Mode
Text Size
Log in / Sign up
Phase 3 N=40 Randomized Single-blind Treatment

Impact of TheraWorx Foam on Symptom Relief in Thumb Arthritis

Arthritis

Enrolled (actual)
40
Serious AEs
0.0%
Results posted
Jul 2021
Primary outcome: Primary: Numeric Pain Rating Scale — 1.7; 2.4; 3.2 units on a scale — p=0.6

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Theraworx (Drug); Placebo (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
John Fowler
Primary completion
Jul 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
Numeric Pain Rating Scale
1.7; 2.4; 3.2 0.6
PRIMARY
Disabilities of the Arm, Shoulder, and Hand (DASH) Score
22.8; 35.9; 26.35 0.59
PRIMARY
Thumb Range of Motion
70; 60; 70 0.9
PRIMARY
Grip Strength
74; 67; 72 0.45
PRIMARY
Pinch Strength
22.5; 29; 25 0.5

Summary

Thumb carpometacarpal osteoarthritis (CMC OA) affects up to 33% of people over the age of 40, which leads to inflammation, pain, and weakness of the CMC joint. Treatment modalities are both conservative and surgical with surgical options including osteotomy, bone excision, ligament reconstruction, and various prosthetic implants. The conservative treatment options, however, are limited to NSAIDs and bracing or steroid injections. Advances in topical therapies have the potential to deliver focused treatment to the CMC joint. Novel treatment of inflammation can potentially reduce inflammation and pain associated with progressing osteoarthritis. Theraworx Relief is an FDA registered foam that has theoretical impact on inflammation reduction in human subjects treated with the topical foam.

Eligibility Criteria

Inclusion Criteria

  • Thumb CMC arthritis
  • greater than or equal to age 18
  • Interested in non-operative treatment of thumb arthritis

Exclusion Criteria

  • Recent corticosteroid injection into the thumb joint
  • Non-English speaking
  • skin lesions or rashes on the thumb
  • current use of topical anti-inflammatory medications
  • concomitant thumb/wrist diagnoses that would impact the results (as determined by the PI)
  • known allergy to magnesium
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03770091). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search